Xcout Intel
Variational AI
Variational AI is a privately held biotechnology startup headquartered in Vancouver, British Columbia. Founded in 2019, the company focuses on drug discovery, utilizing artificial intelligence to identify novel drug-like small molecules. Recognized as an innovative AI enterprise in Canada, it develops advanced computational methods for pharmaceutical research.
Subscribe to see Variational AI’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Variational AI at a glance
Variational AI is a drug discovery company headquartered in Canada. It has raised at least $9M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $5.5M in February 2025. Xcout tracks 11 named people at Variational AI, including Handol Kim (CEO).
Variational AI leadership
- Handol KimCEO
- Handol KimCo-Founder & CEO
- Jason Rolfe, PhDCo-Founder & CTO
- Ali Saberali, PhDCo-Founder & Head of Platform
- Peter Guzzo, PhDEVP, Head of Drug Discovery
- Roslynn Drewitt-LangeVP, Finance & Operations
5 more named people on record for Variational AI, with roles, board committees and tenure — see the full roster →
Variational AI funding rounds
At least $9M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $5.5M | 8 named | |
| — | $3.5M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Variational AI competitors
A few of Variational AI's closest competitors — see the full list of competitors and alternatives →
Iktos is a privately held biotechnology company headquartered in Paris, France, specializing in generative AI and robotics for drug discovery. Its generative AI platform, Makya, designs molecules optimized for robotic synthesis.
Generare is a biotechnology and artificial intelligence company headquartered in Paris, France, focused on commercial bioprospecting and decoding natural products.
Mana.bio is an AI-based drug delivery startup headquartered in Tel Aviv, Israel, focusing on gene therapy and lipid nanoparticle development for mRNA and oligonucleotide therapeutics. The company leverages artificial intelligence to create advanced platforms for next-generation vaccines and genetic medicines.
Renasis Bio Ltd. is a stealth-mode private company headquartered in Rehovot, Israel, established in 2025. The firm is developing an AI-driven drug discovery platform focused on RNA-targeting small molecules to advance RNA druggability.
Prazer Therapeutics is a biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company focuses on developing orally available, brain-penetrating small molecule therapeutics utilizing targeted protein degradation technology for novel drug discovery.
Neurasic Therapeutics is a Montreal-based drug discovery company founded in 2020 and based on research from McGill University's Montreal Neurological Institute. The company develops therapeutic solutions and medicinal drugs aimed at treating neurological disorders, with a primary focus on advancing opiate-sparing, pain-relieving treatments such as substituted thiophene for neuropathic and inflammatory pain.
Get Variational AI's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Variational AI in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access